Additional file 1 of Body mass index and cancer risk among adults with and without cardiometabolic diseases: evidence from the EPIC and UK Biobank prospective cohort studies
Creators: name: Fontvieille, Emma
name: Viallon, Vivian
name: Recalde, Martina
name: Cordova, Reynalda
name: Jansana, Anna
name: Peruchet-Noray, Laia
name: Lennon, Hannah
name: Heath, Alicia K.
name: Aune, Dagfinn
name: Christakoudi, Sofia
name: Katzke, Verena
name: Kaaks, Rudolf
name: Inan-Eroglu, Elif
name: Schulze, Matthias B.
name: Mellemkjær, Lene
name: Tjønneland, Anne
name: Overvad, Kim
name: Farràs, Marta
name: Petrova, Dafina
name: Amiano, Pilar
name: Chirlaque, María-Dolores
name: Moreno-Iribas, Conchi
name: Tin Tin, Sandar
name: Masala, Giovanna
name: Sieri, Sabina
name: Ricceri, Fulvio
name: Panico, Salvatore
name: May, Anne M.
name: Monninkhof, Evelyn M.
name: Weiderpass, Elisabete
name: Gunter, Marc J.
name: Ferrari, Pietro
name: Freisling, Heinz
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Biotechnology
subject: Environmental Sciences not elsewhere classified
subject: Sociology
subject: FOS: Sociology
subject: Biological Sciences not elsewhere classified
subject: Cancer

description: Additional file 1: Figure S1: Flowchart with the inclusion and exclusion criteria of the study population, in UK Biobank; Figure S2: Flowchart with the inclusion and exclusion criteria of the study population, in EPIC; Table S1: Diagnostic codes for the definition of cancer, type 2 diabetes and cardiovascular diseases; Table S2: Main characteristics of both cohorts; Figure S3: Directed Acyclic Graph (DAG) describing the potential causal and confounding effects of obesity on cancer risk; Figure S4: Framework to study the natural history of multimorbidity in UKB and EPIC with cancer as the index disease and T2D and CVD as comorbidities; Table S3: Association between BMI (per 1 standard deviation increment) and cancer risk by ascertainment of incident cardiometabolic conditions, in EPIC and UKB cohorts, in men; Figure S5: Forest plot of the associations (with 95% CIs) between BMI and cancer risk depending on cardiometabolic status in EPIC and UKB cohorts and the results of the meta-analysis (random-effects models), in men; Table S4: Association between BMI (per 1 standard deviation increment) and cancer risk by ascertainment of incident cardiometabolic conditions, in EPIC and UKB cohorts, in women; Figure S6: Forest plot of the associations (with 95% CIs) between BMI and cancer risk depending on cardiometabolic status in EPIC and UKB cohorts and the results of the meta-analysis (random-effects models), in women; Table S5: Association between BMI (per 1 standard deviation increment) and cancer risk by ascertainment of incident cardiometabolic conditions, with 95% CIs, in UKB. Models further adjusted for metformin use; Table S6: Association between body mass index (per 1 standard deviation increment) and cancer risk by ascertainment of incident cardiometabolic conditions, with 95% CIs, in UKB. Models further adjusted for statin use; Table S7: Association between BMI (per 1 standard deviation increment) and cancer risk by ascertainment of incident cardiometabolic conditions, in EPIC and UKB cohorts, among never smokers; Table S8: Association between BMI (per 1 standard deviation increment) and cancer risk (total cancers and non-obesity-related cancers) by ascertainment of incident cardiometabolic conditions, in EPIC and UKB cohorts; Figure S7: Forest plot of the associations (with 95% CIs) between BMI and cancer risk (total cancers and non-obesity-related cancers) by ascertainment of incident cardiometabolic conditions, in EPIC and UKB cohorts and the results of the meta-analysis (random-effects models); Table S9: Relative excess risk of all-cancers due to interaction between overweight and/or obesity and incident cardiometabolic diseases, in EPIC and UKB cohorts, in men; Figure S8: Forest plot of the relative excess risk of all-cancers due to interaction (with 95% CIs) between overweight and/or obesity and incident cardiometabolic diseases in EPIC and UKB cohorts and the results of the meta-analysis (random-effects models), in men; Table S10: Relative excess risk of all-cancers due to interaction between overweight and/or obesity and incident cardiometabolic diseases, in EPIC and UKB cohorts, in women; Figure S9: Forest plot of the relative excess risk of all-cancers due to interaction (with 95% CIs) between overweight and/or obesity and incident cardiometabolic diseases in EPIC and UKB cohorts and the results of the meta-analysis (random-effects models), in women; Table S11: Relative excess risk of all-cancers due to interaction between overweight and/or obesity and incident cardiometabolic diseases, in EPIC and UKB cohorts, among never smokers; Figure S10: Forest plot of the relative excess risk of all-cancers due to interaction (with 95% CIs) between overweight and/or obesity and incident cardiometabolic diseases, in EPIC and UKB cohorts and the results of the meta-analysis (random-effects models); Table S12: Relative excess risk of all-cancers due to interaction between overweight and/or obesity and incident cardiometabolic diseases, in EPIC and UKB cohorts; Table S13: Relative excess risk of all-cancers due to interaction between overweight and/or obesity and incident cardiometabolic diseases, in EPIC and UKB cohorts. Models further adjusted for metformin use; Table S14: Relative excess risk of all-cancers due to interaction between overweight and/or obesity and incident cardiometabolic diseases, in EPIC and UKB cohorts. Models further adjusted for statin use.